- Peyronie's is "tailor-made for [the company's] urology-focused specialty sales force," Aegis says, regarding the new PD indication for Auxilium Pharmaceuticals' (AUXL -1.3%) Xiaflex.
- Analyst Ram Selvaraju also notes that "the significantly higher number of vials of Xiaflex required to treat each Peyronie's disease patient is likely to translate into much greater revenue per patient in this indication vs. Dupuytren's contracture."
- Buy rating and $33 target maintained.
Aegis reiterates bullish outlook for Auxilium
Dec 11 2013, 10:50 ET